Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

Experimental Hematology

Volumn 29, Issue 4, 2001, Pages 441-447

  Cruz, Jose C ^a   Alsina, Melissa ^b   Craig, Fiona ^c   Yoneda, Toshiyuki ^b   Anderson, Judith L ^b   Dallas, Mark ^b   Roodman, G David ^b,d  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

ABDOMINAL TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DISEASE; BONE LESION; BONE MARROW CULTURE; CANCER GRAFT; CELL STIMULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE COURSE; DOSE TIME EFFECT RELATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IRRADIATION; LEUKEMIA CELL LINE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; PARAPLEGIA; PLASMA CELL; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; BONE DISEASES; BONE MARROW CELLS; CELL DIVISION; CELL SURVIVAL; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; HYPERCALCEMIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; LEUKEMIA, PLASMACYTIC; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; OSTEOLYSIS; PARAPLEGIA; TUMOR CELLS, CULTURED;

MURINAE;

EID: 0035052888     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00618-X     Document Type: Article

References (23)

1. Mechanisms of bone lesions in multiple myeloma and lymphoma
2. Bone destruction and hypercalcemia in plasma cell myeloma
3. Current use of bisphosphonates in oncology
4. Bisphosphonates in multiple myeloma
5. Management of acute hypercalcemia
6. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
7. Bisphosphonates induce apoptosis in human myeloma cells; a novel antitumor activity
8. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
9. Establishment of a human plasma cell line in vitro
10. Ibandronate in malignant bone disease and osteoporosis; clinical results
11. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
12. Targeting Simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts
13. Identification of committed mononuclear precursors for osteoclast-like cells formed in long-term marrow cultures
14. Sequential expression of phenotype markers for osteoclasts during differentiation of precursors for multinucleated cells formed in long-term human marrow cultures
15. Osteoclast-like cells formed in long-term human bone marrow cultures express a similar surface phenotype as authentic osteoclasts
16. Development of an in vivo model of human multiple myeloma bone disease
17. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
18. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
19. A third-generation bisphosphonate, YM175, inhibits osteoclast formation in murine cocultures by inhibiting proliferation of precursor cells via supporting cell-dependent mechanisms
20. Macrophage inflammatory protein 1-α (MIP-1α) is a potential osteoclast stimulatory factor in multiple myeloma
21. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease